AD Pipeline Update: LEO Pharma Reports Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe AD May 12, 2025
PsO Pipeline Watch: Oral IL-23 Blocker Icotrokinra Produces Significant Skin Clearance in Patients with Scalp and Genital PsO May 9, 2025
2025 SID Annual Meeting Coverage: Artax Biopharma’s Oral Nck Modulator Shows Promise in PsO May 9, 2025
2025 SID Annual Meeting Coverage: Mayo Clinic Insights on Biologics and Patient Outcomes in HS May 9, 2025